Iradimed (NASDAQ:IRMD - Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of $0.45 per share and revenue of $19.20 million for the quarter. Persons that are interested in participating in the company's earnings conference call can do so using this link.
Iradimed Trading Down 2.0 %
Shares of NASDAQ IRMD traded down $1.21 during trading on Friday, reaching $60.15. The company had a trading volume of 31,970 shares, compared to its average volume of 36,478. The stock has a 50-day moving average price of $56.77 and a two-hundred day moving average price of $51.77. Iradimed has a twelve month low of $40.18 and a twelve month high of $63.29. The stock has a market capitalization of $762.10 million, a PE ratio of 41.20 and a beta of 0.82.
Insider Activity
In other Iradimed news, CFO John Glenn sold 2,500 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the completion of the transaction, the chief financial officer now owns 4,383 shares in the company, valued at $237,470.94. This represents a 36.32 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 37.10% of the company's stock.
Analyst Ratings Changes
Separately, StockNews.com downgraded shares of Iradimed from a "strong-buy" rating to a "buy" rating in a research note on Wednesday.
Check Out Our Latest Research Report on IRMD
Iradimed Company Profile
(
Get Free Report)
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Featured Articles
Before you consider Iradimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iradimed wasn't on the list.
While Iradimed currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
